technologies to address conditions that are not responsive to traditional therapeutic approaches. The platform involves a novel strategy for linking antibodies to protein-degrading components, aiming to extend therapeutic reach. The company’s research is centered around applications in immunology, oncology, and other disease areas driven by pathogenic proteins. Solu Therapeutics also works on optimizing pharmacokinetics and safety profiles for its biologics to enhance clinical potential. Its development pipeline includes preclinical programs advancing toward investigational new drug applications.